Heterogeneity in residual function of MeCP2 carrying missense mutations in the methyl CpG binding domain

Journal of Medical Genetics

Volumn 40, Issue 7, 2003, Pages 487-493

  Kudo, S ^a   Nomura, Y ^b   Segawa, M ^b   Fujita, N ^c   Nakao, M ^c   Schanen, C ^d   Tamura, M ^b  

^a HOKKAIDO INSTITUTE OF PUBLIC HEALTH   (Japan)

^b Segawa Neurological Clinic for Children   (Japan)

^c KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^d NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; METHYL CPG BINDING PROTEIN; METHYL CPG BINDING PROTEIN 2; METHYL GROUP; MUTANT PROTEIN; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL LINE; DROSOPHILA; GENETIC HETEROGENEITY; HETEROCHROMATIN; MISSENSE MUTATION; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; RETT SYNDROME; TRANSCRIPTION REGULATION;

ANIMALIA;

EID: 0037488244     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.40.7.487     Document Type: Article

References (48)

1. Hagberg B, Aicardi J, Dias K, Ramos, O. A progressive syndrome of autism, dementia, ataxia and loss of purposeful hand use in girls: Rett's syndrome; report of 35 cases. Ann Neurol 1983;14:471-9.
2. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999;23:185-8.
3. Bird A, Wolffe AP. Methylation-induced repression-belts, braces, and chromatin. Cell 1999;99:451-4.
4. Wakefield RID, Smith BO, Nan X, Free A, Soteriou A, Uhrin D, Bird AP, Barlow PN. The solution structure of the domain from MeCP2 that binds to methylated DNA. J Mol Biol 1999;291:1055-65.
5. Ohki I, Shimotake N, Fujita N, Nakao M, Shirakawa M. Solution structure of the methyl-CpG-binding domain of the methylation-dependent transcriptional repressor MBD1. EMBO J 1999;18:6653-61.
6. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:386-9.
7. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998;19:187-9.
8. Shahbazian MD, Zoghbi HY. Molecular genetics of Rett syndrome and clinical spectrum of MECP2 mutations. Curr Opin Neurol 2000;14:171-6.
9. Guy J, Hendrich B, Holmes M, Martin JE, Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 2001;27:322-6.
10. Chen RZ, Akbarian S, Tudor M, Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 2001;27:327-31.
11. Shahbazian MD, Young JI, Yuva-Paylor LA, Spencer CM, Antalffy BA, Noebels JL, Armstrong DL, Paylor R, Zoghbi HY. Mice with truncated MeCP2 recapitulate Rett syndrome features and display hyperacetylation of histone H3. Neuron 2002;35:243-54.
12. Hammer S, Dorrani N, Dragich J, Kudo S, Schanen C. The phenotypic consequences of MECP2 mutations extend beyond Rett syndrome. Ment Retard Dev Disabil Res Rev 2002;8:94-8.
13. Kudo S, Nomura Y, Segawa M, Fujita N, Nakao M, Dragich J, Schanen C, Tamura M. Functional analyses of MeCP2 mutations associated with Rett syndrome using transient expression systems. Brain Dev 2001;23:S165-73.
14. Kudo S, Nomura Y, Segawa M, Fujita N, Nakao M, Hammer S, Schanen C, Terai I, Tamura M. Functional characterization of MeCP2 mutations found in male patients with X linked mental retardation. J Med Genet 2002;39:132-6.
15. Ohki I, Shimotake N, Fujita N, Jee JG, Ikegami T, Nakao M, Shirakawa M. Solution structure of the methyl-CpG-binding domain of human MBD1 in complex with methylated DNA. Cell 2001;105:487-97.
16. Orrico A, Lam C-W, Galli L, Dotti MT, Hayek G, Tong S-F, Poon PMK, Zappella M, Federico A, Sorrentino V. MECP2 mutation in male patients with non-specific X-linked mental retardation. FEBS Lett 2000;481:285-8.
17. Couvert P, Bienvenu T, Aquaviva C, Poirier K, Moraine C, Gendrot C, Verloes A, Andres C, Le Fevre AC, Souville I, Steffann J, des Portes V, Ropers HH, Yntema HG, Fryns J-P, Briault S, Chelly J, Cherif B. MECP2 is highly mutated in X-linked mental retardation. Hum Mol Genet 2001;10:941-6.
18. Amir RE, Zoghbi H. Rett syndrome: Methyl-CpG-binding protein 2 mutations and phenotype-genotype correlations. Am J Med Genet 2000;97:147-52.
19. Huppke P, Laccone F, Kramer N, Engel W, Hanefeld F. Rett syndrome: analysis of MECP2 and clinical characterization of 31 patients. Hum Mol Genet 2000;9:1369-75.
20. Xiang F, Buervenich S, Nicolao P, Bailey ME, Zhang Z, Anvret M. Mutation screening in Rett syndrome patients. J Med Genet 2000;37:250-5.
21. Cheadle JP, Gill H, Fleming N, Maynard J, Kerr A, Leonard H, Krawczak M, Cooper DN, Lynch S, Thomas N, Hughes H, Hulten M, Ravine D, Sampson JR, Clarke A. Long-read sequence analysis of the MECP2 gene in Rett syndrome patients: correlation of disease severity with mutation type and location. Hum Mol Genet 2000;9:1119-29.
22. Vacca M, Filippini F, Budillon A, Rossi V, Mercadante G, Manzati E, Gualandi F, Bigoni S, Trabanelli C, Pini G, Calzolari E, Ferlini A, Meloni I, Hayek G, Zappella M, Renieri A, D'Urso M, D'Esposito M, MacDonald F, Kerr A, Dhanjal S, Huhen M. Mutation analysis of the MECP2 gene in British and Italian Rett syndrome females. J Mol Med 2001;78:648-55.
23. De Bona C, Zappella M, Hayek G, Meloni I, Vitelli F, Bruttini M, Cusano R, Loffredo P, Longo I, Renieri A. Preserved speech variant is allelic of classic Rett syndrome. Eur J Hum Genet 2000;8:325-30.
24. Obata K, Matsuishi T, Yamashita Y, Fukuda T, Kuwajima K, Horiuchi I, Nagamitsu S, Iwanaga R, Kimura A, Omori I, Endo S, Mori K, Kondo I. Mutation analysis of the methyl-CpG binding protein 2 gene (MECP2) in patients with Rett syndrome. J Med Genet 2000;37:608-10.
25. Hampson K, Woods CG, Latif F, Webb T. Mutations in the MECP2 gene in a cohort of girls with Rett syndrome. J Med Genet 2000;37:610-12.
26. Buyse IM, Fang P, Hoon KT, Amir RE, Zoghbi HY, Roa BB. Diagnostic testing for Rett syndrome by DHPLC and direct sequencing analysis of the MECP2 gene: identification of several novel mutations and polymorphisms. Am J Hum Genet 2000;67:1428-36.
27. Hoffbuhr K, Devaney JM, LaFleur B, Sirianni N, Scacheri C, Giron J, Schuette J, Innis J, Marino M, Philippart M, Narayanan V, Umansky R, Kronn D, Hoffman EP, Naidu S. MeCP2 mutations in children with and without the phenotype of Rett syndrome. Neurology 2001;56:1486-95.
28. Inui K, Akagi M, Ono J, Tsukamoto H, Shimono K, Mano T, Imai K, Yamada M, Muramatsu T, Sakai N, Okada S. Mutational analysis of MECP2 in Japanese patients with atypical Rett syndrome. Brain Dev 2001;23:212-5.
29. Laccone F, Huppke P, Hanefeld F, Meins M. Mutation spectrum in patients with Rett syndrome in the German population: evidence of hot spot regions. Hum Mutat 2001;17:183-90.
30. Nielsen JB, Henriksen KF, Hansen C, Silahtaroglu A, Schwartz M, Tommerup N. MECP2 mutations in Danish patients with Rett syndrome: high frequency of mutations but no consistent correlations with clinical severity or with the X chromosome inactivation pattern. Eur J Hum Genet 2001;9:178-84.
31. Chae JH, Hwang YS, Kim KJ. Mutation analysis of MECP2 and clinical characterization in Korean patients with Rett syndrome. J Child Neurol 2002;17:33-6.
32. Villard L, Cardoso AK, Chelly PJ, Tardieu PM, Fontes M. Two affected boys in a Rett syndrome family: clinical and molecular findings. Neurology 2000;55:1188-93.
33. Kudo S, Fukuda M. Tissue-specific transcriptional regulation of human leukosialin (CD43) gene is achieved by DNA methylation. J Biol Chem 1995;270:13298-302.
34. Lewis JD, Meehan RR, Henzel WJ, Maurer-Fogy I, Jeppesen P, Klein F, Bird A. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 1992;69:905-14.
35. Nan X, Tate P, Li E, Bird A. DNA methylation specifies chromosomal localization of MeCP2. Mol Cell Biol 1996;16:414-21.
36. Lyko F. DNA methylation learns to fly. Trends in Genet 2001;17:169-72.
37. Kudo S. Methyl-CpG-binding protein MeCP2 represses Sp1-activated transcription of the human leukosialin gene when the promoter is methylated. Mol Cell Biol 1998;18:5492-9.
38. Courey AJ, Tjian R. Analysis of Sp1 in vivo reveals multiple transcriptional domains, including a novel glutamine-rich activation motif. Cell, 1988;55:887-98.
39. Free A, Wakefield RID, Smith BO, Dryden DTF, Barlow PN, Bird A. DNA recognition by the methyl-CpG binding domain of MeCP2. J Biol Chem 2000;276:3353-60.
40. Hendrich B, Bird A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol 1998;18:6538-47.
41. Wade PA, Wolffe AP. ReCoGnizing methylated DNA. Nat Struct Biol 2001;8:575-7.
42. Ballestar E, Yusufzai TM, Wolffe AP. Effects of Rett syndrome mutations of the methyl-CpG binding domain of the transcriptional repressor MeCP2 on selectivity for association with methylated DNA. Biochemistry 2000;39:7100-6.
43. Abroad K, Henikoff S. Epigenetic consequences of nucleosome dynamics. Cell 2002;111:281-4.
44. Uchino J, Suzuki M, Hoshino K, Nomura Y, Segawa M. Development of language in Rett syndrome. Brain Dev 2001;23:S233-5.
45. Yamashita Y, Kondo I, Fukuda T, Morishima R, Kusaga A, Iwanaga R, Matsuishi T. Mutation analysis of the methyl-CpG-binding protein 2 gene (MECP2) in Rett patients with preserved speech. Brain Dev 2001;23:S157-60.
46. Monros E, Armstrong J, Aibar E, Poo P, Canos I, Pineda M. Rett syndrome in Spain: mutation analysis and clinical correlations. Brain Dev 2001;23:S251-3.
47. Zappella M, Meloni I, Longo I, Hayek G, Renieri A. Preserved speech variants of the Rett syndrome: molecular and clinical analysis. Am J Med Genet 2001;104:14-22.
48. Armstrong J, Poo P, Pineda M, Aibar E, Gean E, Catala V, Monros E. Classic Rett syndrome in a boy as a result of somatic mosaicism for a MECP2 mutation. Ann Neurol 2001;50:692.